The stock of NeuroSense Therapeutics Ltd (NRSN) has seen a -3.54% decrease in the past week, with a 9.77% gain in the past month, and a 107.92% flourish in the past quarter. The volatility ratio for the week is 8.04%, and the volatility levels for the past 30 days are at 10.74% for NRSN. The simple moving average for the past 20 days is -10.24% for NRSN’s stock, with a 52.96% simple moving average for the past 200 days.
Is It Worth Investing in NeuroSense Therapeutics Ltd (NASDAQ: NRSN) Right Now?
The stock has a 36-month beta value of 1.64. Opinions on the stock are mixed, with 2 analysts rating it as a “buy”, 0 as “overweight”, 1 as “hold”, and 0 as “sell”.
The public float for NRSN is 17.38M, and at present, short sellers hold a 2.27% of that float. On July 04, 2025, the average trading volume of NRSN was 274.12K shares.
NRSN stock’s latest price update
The stock of NeuroSense Therapeutics Ltd (NASDAQ: NRSN) has increased by 0.53% when compared to last closing price of $1.9.Despite this, the company has seen a loss of -3.54% in its stock price over the last five trading days. benzinga.com reported 2025-05-12 that Last Wednesday, NeuroSense Therapeutics Ltd. NRSN said it scaled up its production of PrimeC to a commercial scale.
NRSN Trading at 18.39% from the 50-Day Moving Average
After a stumble in the market that brought NRSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.54% of loss for the given period.
Volatility was left at 10.74%, however, over the last 30 days, the volatility rate increased by 8.04%, as shares surge +12.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +89.11% upper at present.
During the last 5 trading sessions, NRSN fell by -3.54%, which changed the moving average for the period of 200-days by +41.48% in comparison to the 20-day moving average, which settled at $2.1280. In addition, NeuroSense Therapeutics Ltd saw 76.85% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
N/A, the N/A of NeuroSense Therapeutics Ltd, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for NRSN
The total capital return value is set at -3.83%. Equity return is now at value -2880.11%, with -263.45% for asset returns.
The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -4.11.
Currently, EBITDA for the company is -9.88 million with net debt to EBITDA at 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.21.
Conclusion
To sum up, NeuroSense Therapeutics Ltd (NRSN) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
